Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC‐Norfolk prospective population‐based cohort study
Open Access
- 27 February 2022
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (7) , 3297-3306
Abstract
Background: Higher medication anticholinergic burden is associated with increased risk of cardiovascular disease and cognitive decline. A mechanistic pathway has not been established. We aimed to determine whether inflammation may mediate these associations.Methods: Participants were drawn from the European Prospective Investigation into Cancer, Norfolk cohort (40‐79 years at baseline). Anticholinergic burden score (ACB) was calculated at first (1HC) (1993/97) and second (2HC) (1998/2000) health checks. Fibrinogen and C‐reactive protein (CRP) were measured during 1HC and tumour necrosis factor alpha (TNF‐α) and interleukin 6 (IL‐6) during 2HC. Cross‐sectional associations between ACB and inflammatory markers were examined for both health checks. Prospective associations were also examined between 1HC ACB and 2HC inflammatory markers. Models were adjusted for age, sex, lifestyle factors, comorbidities and medications.Results: In total, 17 678 and 22 051 participants were included in cross‐sectional analyses for CRP, and fibrinogen, respectively. Furthermore, 5101 participants with data on TNF‐α and IL‐6 were included in the prospective analyses. Cross‐sectionally, compared to ACB = 0, ACB ≥ 4 was associated with higher fibrinogen, beta (95% confidence interval) = 0.134 g/L (0.070, 0.199), CRP 1.175 mg/L (0.715, 1.634), IL‐6 0.593 pg/mL (0.254, 0.932) and TNF‐α 0.137 pg/mL (0.033, 0.241). In addition, a point increase in ACB was associated with higher levels of all markers. Prospectively, compared to ACB = 0, ACB ≥ 4 was associated with higher IL‐6(pg/mL) of 0.019 (−0.323, 0.361) and TNF‐α (pg/mL) of 0.202% (0.81, 0.323). A unit increase in ACB was associated with a significantly higher TNF‐α and IL‐6.Conclusion: Higher ACB was associated with higher inflammatory markers. Inflammation may mediate the relationship between anticholinergic medications and adverse outcomes.Keywords
All Related Versions
Funding Information
- Cancer Research UK (C864/A14136)
- Medical Research Council (MC‐UU_12015/1, MR/N003284/1)
This publication has 30 references indexed in Scilit:
- Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysisEuropean Heart Journal, 2013
- Inflammatory Markers and Gait Speed Decline in Older AdultsThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2011
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysisThe Lancet, 2010
- The cognitive impact of anticholinergics: A clinical reviewClinical Interventions in Aging, 2009
- C-reactive protein and risk of heart failure. The Rotterdam StudyAmerican Heart Journal, 2006
- The role of IL-6 and STAT3 in inflammation and cancerEuropean Journal of Cancer, 2005
- Inflammatory markers and cardiovascular health in older adultsCardiovascular Research, 2005
- Abnormalities in cardiac baroreceptor sensitivity in acute ischaemic stroke patients are related to aortic stiffnessClinical Science, 2005
- Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging studyAnnals of Neurology, 2002
- Inflammation and AtherosclerosisCirculation, 2002